Ebola disease – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 19 Jun 2026 04:03:07 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Ebola disease – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Long-Term Immunity of the Ebola Vaccine VSV-EBOV and Booster Dose for Workers at Risk of Ebola Exposure https://clinicaltrials.eu/trial/study-on-the-long-term-immunity-of-the-ebola-vaccine-vsv-ebov-and-booster-dose-for-workers-at-risk-of-ebola-exposure/ Wed, 29 Apr 2026 15:05:48 +0000 https://clinicaltrials.eu/trial/study-on-the-long-term-immunity-of-the-ebola-vaccine-vsv-ebov-and-booster-dose-for-workers-at-risk-of-ebola-exposure/ This clinical trial is focused on studying the effectiveness of a vaccine called Ervebo, which is used to protect against Ebola virus infection. The vaccine is a solution for injection and is designed to help the body build immunity against the Ebola virus. The study aims to understand how long the immunity lasts after receiving the vaccine and to assess the benefits of an additional booster dose for people who might be at risk of coming into contact with the Ebola virus due to their work.

The purpose of the study is to compare the immune response in individuals who receive the Ervebo vaccine with and without a booster dose. Participants will receive the initial vaccination and then, after six months, some will receive a booster dose while others will not. The study will monitor the participants’ immune responses over a period of 24 months to see how well the vaccine works in maintaining immunity against the Ebola virus.

Throughout the study, participants will have their blood tested to measure the levels of antibodies, which are proteins the body makes to fight infections like the Ebola virus. The study will also keep track of any side effects that occur after the vaccinations. This research is important for understanding how to best protect people who might be exposed to the Ebola virus in their work environments.

]]>